Video

Dr. Lee on Cirmtuzumab/Ibrutinib Dosing in MCL and CLL

Author(s):

Hun Ju Lee, MD

In Partnership With:

Hun Ju Lee, MD, discusses dosing of the combination of the investigational ROR1 inhibitor cirmtuzumab and ibrutinib in mantle cell lymphoma and chronic lymphocytic leukemia.

Hun Ju Lee, MD, an associate professor of medicine, Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, discusses dosing of the combination of the investigational ROR1 inhibitor cirmtuzumab and ibrutinib (Imbruvica) in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).

At the 2020 ASCO Virtual Scientific Program, findings from a phase 1b/2 trial showed that a 600 mg flat dose of cirmtuzumab plus 420 mg/day of ibrutinib in CLL and 560 mg/day in MCL was selected for part 2 of the expansion cohort.

The combination was well tolerated, says Lee. Grade 1/2 adverse effects consisted mainly of diarrhea, confusion, and fatigue among patients with MCL or CLL.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
Yucai Wang, MD, PhD
July 23rd 2024

Study Shows Real-World Benefit of Rituximab Maintenance After Frontline BR in Mantle Cell Lymphoma

Robert Z. Orlowski, MD, PhD, Florence Maude Thomas Cancer Research Professorship, Department of Lymphoma/Myeloma, director, Section of Myeloma, professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
July 11th 2024

Orlowski on Isa-VRd in Transplant-Ineligible Multiple Myeloma

Michael Wang, MD, professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
July 18th 2024

Ibrutinib Plus Venetoclax Generates Durable CRs in TP53+ Mantle Cell Lymphoma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Tycel Phillips, MD
July 15th 2024

The Shifting MCL Treatment Paradigm Raises Sequencing Questions

Tycel Phillips, MD, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
July 10th 2024

Phillips Discusses Past Progress and Previews the Future in Hematologic Cancers